KERRI MOORE: Open Payments
NPI 1336604214 · TOPEKA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,381 in 142 payments from 11 companies in 2025. Trend: 2023 $1,879 · 2024 $1,578 · 2025 $2,381
Food & beverage: $2,381
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 26 | $581 |
| Otsuka America Pharmaceutical, Inc. | 20 | $412 |
| Alkermes, Inc. | 21 | $287 |
| Vanda Pharmaceuticals Inc. | 19 | $266 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $231 |
| Teva Pharmaceuticals USA, Inc. | 25 | $215 |
| Lundbeck LLC | 7 | $141 |
| ABBVIE INC. | 10 | $139 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 2 | $33 |
Products named: COBENFY, REXULTI, ARISTADA, HETLIOZ, CAPLYTA, AUSTEDO XR, ABILIFY MAINTENA, VRAYLAR.
Industry payments across KS — which companies pay providers there.
